Whole-exome sequencing in tumor samples from sequenom-wild-type, ALK negative stage IV lung adenocarcinoma (ADC) patients (p).

Authors

Enriqueta Felip

Enriqueta Felip

Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain

Enriqueta Felip , Ginevra Caratu , Daniel Silberschmidt , Pablo Martinez , Alex Martinez Marti , Susana Cedres , Nuria Murtra-Garrell , Alejandro Navarro-Mendivil , Ludmila Prudkin , Jose Jimenez , Pilar de la Morena , Mercedes Canela , Paolo Nuciforo , Hector G. Palmer , Ana Vivancos

Organizations

Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain, Cancer Genomics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain, Molecular Pathology Laboratory, Vall d'Hebron Institute of Oncology, Barcelona, Spain, Thoracic Surgery Department, Vall d'Hebron University Hospital, Barcelona, Spain, Stem Cells and Cancer Laboratory, Vall d'Hebron Institute of Oncology, Barcelona, Spain

Research Funding

No funding sources reported

Background: The majority of lung ADC tumors are characterized by specific genetic features with KRAS mutations (mut) seen in 20-30%, EGFR mut in 15%, EML4-ALK translocations in 5%, and ERBB2 mut in 2%, among others. Some of these genetic alterations are already being used for selecting targeted therapies. However, identification of additional genomic alterations is required. Methods: In the present ongoing study we perform whole-exome sequencing in paraffin-embedded tumor samples from OncoCarta v1.0 panel wild-type (no mut in hotspots of KRAS, EGFR, ERBB2, AKT1, BRAF, PIK3CA genes) and ALK negative (by FISH) stage IV ADC lung cancer p, and in their matched normal tissue samples. Results: To date, a total of 7 tumors and matched normal tissues have been successfully analyzed. We have detected mut in previously identified ADC genes, such as ERBB2, CTNNB1, TP53, SMAD4 or APC. Interestingly, mut were found in genes belonging to the proposed new cancer hallmark ‘epigenetic and RNA regulation’, such as BRD3, EPC1, PHF1 in almost every p included in our study. Regarding alterations that could be considered relevant for lung tumor pathogenesis/growth or as potential targets for treatment therapies, we were able to identify candidates in 4 of the 7 p. In one p, a case of a transmembrane domain ERBB2mut in exon 20 (p.E770delinsEAYVM) not previously detected by the OncoCarta v1.0 panel (that interrogates L755P, G776S/L/V/C, A775_G776insYVMA, P780_Y781insGSP, S779_P780insVGS mut) was found. In another p, three somatic mut in the BRCA1/2 genes were detected. Additionally, one p had an ALK point mut (p.P336K), for which no functional information is available, together with an APC mutation. In the remaining p, a non-hotspot mutation (although previously detected in a colorectal tumor) was found in CTNNB1. Conclusions: In this limited experience of whole-exome sequencing of a subgroup of stage IV lung ADC p, potentially targetable alterations not formerly detected by other techniques were found. We believe that genomic approaches to detecting alterations may be useful in clinical practice and will hopefully provide assistance in making treatment decisions.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2013 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer - Non-small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Citation

J Clin Oncol 31, 2013 (suppl; abstr 8070)

DOI

10.1200/jco.2013.31.15_suppl.8070

Abstract #

8070

Poster Bd #

36B

Abstract Disclosures

Similar Abstracts

Abstract

2023 ASCO Gastrointestinal Cancers Symposium

Circulating tumor DNA–based genomic landscape of KRAS wild-type pancreatic adenocarcinoma.

First Author: Brendon Fusco

First Author: Silvia Sequero-Lopez

First Author: Nilesh Verma

Abstract

2023 ASCO Annual Meeting

Frequency and patterns of TP53 mutations in lung cancer.

First Author: Yaxian Yang